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Aims Multiple trials have shown that implantable cardioverter deﬁbrillators (ICDs) prolong survival in secondary and
primary prevention populations. However, in spite of the efﬁcacy of these devices in terminating life-threatening
arrhythmias, total mortality remains high.
Methods
and results
We evaluated 1703 patients (mean age: 67+12 years, 82% male) with conventional ICD indications, who were
enrolled and followed between 2001 and 2004 at 128 US centres. Patients were followed for up to a year, and
vital status was obtained for 1655 patients (97%, median follow-up: 377 days). There were 183 deaths within
1 year of ICD implantation (1-year mortality rate: 16%). Predictors of mortality included a history of atrial ﬁbrillation
(AF, P , 0.0001), diabetes (P ¼ 0.0001), failure to use cholesterol-lowering medications (P , 0.001), use of digitalis
and derivatives (P , 0.0001), use of diuretics (P , 0.0001), low body mass index (BMI, P , 0.0001), increasing age
(P , 0.0001), low left ventricular ejection fraction (P , 0.0001), low activity hours (P , 0.0001), elevated resting
heart rate (P ¼ 0.014), low mean arterial pressure (MAP, P ¼ 0.007), and poor functional status (New York Heart
Association class, P , 0.0001). In multivariate modelling, AF (P   0.001), diabetes (P ¼ 0.004), BMI (P ¼ 0.001),
MAP (P ¼ 0.040), and functional class (P ¼ 0.006) predicted mortality.
Conclusion In this population undergoing ICD implantation, poor functional status, low MAP, diabetes, low BMI, and AF were
strongly associated with death within a year.
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Introduction
Multiple clinical trials have shown that automatic implantable car-
dioverter deﬁbrillators (ICDs) reduce mortality in both second-
ary
1–3 and primary
4,5 prevention populations. Nevertheless,
even with the use of ICDs, total mortality was high in these
trials, primarily due to non-arrhythmic causes of death in this
population. Improved understanding of the risk factors for mor-
tality despite ICD implantation would be beneﬁcial: it is possible
that identifying high-risk patients would enable physicians to
better target interventions that would enhance survival. It is
also possible that some populations are at such high risk of non-
arrhythmic death that ICD implantation is futile. To better
understand the predictors of mortality following ICD implan-
tation, we analysed 1-year mortality in patients enrolled in the
Synergistic Effects of Risk Factors for Sudden Cardiac Death
(SERF) Study: a large-scale, multi-centre, prospective study
examining the effect of several risk factors commonly observed
in ICD patients on mortality and spontaneous arrhythmias after
device implantation for standard clinical indications. We are
only reporting on the predictors of mortality following ICD
implantation in this manuscript.
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The SERF Registry prospectively acquired data on 1703 patients under-
going initial ICD implantation for conventional indications at 128 US
centres between the years 2001and 2004. The patients received
either a Guidant VENTAKw PRIZMTM, VENTAKw PRIZMTM HE, or
VENTAKw PRIZMTM 2 ICD (Guidant Corp., St Paul, MN, USA).
Device programming was left to the discretion of the implanting phys-
ician. Patients were followed up to 1 year with scheduled device inter-
rogations at 6-month intervals. One-year follow-up was actually 390
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Table 1 Baseline demographics and patient history of SERF study participants
Baseline demographics/history
Risk factor Overall (n 5 1655) Survivors (n 5 1472) Non-survivors (n 5 183) x
2
n (%) n (%) n (%) P-value
Age 66.81+11.69 66.26+11.74 71.23+10.28
,0.0001
Age , 65 643 (39%) 603 (41%) 40 (22%)
65   age , 80 818 (49%) 702 (48%) 116 (63%)
80   age 184 (11%) 157 (11%) 27 (15%)
Unknown 10 (,1%) 10 (,1%) 0 (0%)
Gender 0.383
Female 296 (18%) 259 (18%) 37 (20%)
Male 1359 (82%) 1213 (82%) 146 (80%)
NYHA ,0.0001
I 310 (19%) 296 (20%) 14 (8%)
II 685 (41%) 616 (42%) 69 (38%)
III 399 (24%) 329 (22%) 70 (38%)
IV 37 (2%) 24 (2%) 13 (7%)
Unknown 224 (14%) 207 (14%) 17 (9%)
BMI ,0.0001
BMI , 22 164 (10%) 127 (9%) 37 (20%)
22   BMI,25 269 (16%) 227 (15%) 42 (23%)
25   BMI , 30 634 (38%) 579 (39%) 55 (30%)
30   BMI 564 (34%) 519 (35%) 45 (25%)
Unknown 24 (1%) 24 (1%) 20 (1%)
Resting heart rate 0.021
Rest HR  80 1261 (76%) 1136 (77%) 125 (68%)
80 ,rest HR 375 (23%) 322 (22%) 53 (29%)
Unknown 19 (1%) 19 (1%) 14 (1%)
MAP 0.011
MAP   90 896 (54%) 780 (53%) 116 (63%)
90 , MAP 737 (45%) 671 (46%) 66 (36%)
Unknown 22 (1%) 21 (1%) 1 (,1%)
LVEF 31.72+12.38 32.16+12.40 28.17+11.72
,0.0001
LVEF , 20 172 (10%) 137 (9%) 35 (19%)
20   LVEF , 30 504 (30%) 445 (30%) 59 (32%)
30   LVEF , 40 545 (33%) 489 (33%) 56 (31%)
40   LVEF 393 (24%) 365 (25%) 28 (15%)
Unknown 41 (2%) 36 (2%) 5 (3%)
Syncope 571 (35%) 506 (34%) 65 (36%) 0.734
Prior MI 1195 (72%) 1066 (72%) 129 (70%) 0.564
Spontaneous non-sustained VT 1120 (68%) 987 (67%) 133 (73%) 0.132
Atrial ﬁbrillation 433 (26%) 358 (24%) 75 (41%) ,0.0001
Hypertension 962 (58%) 861 (58%) 101 (55%) 0.715
Currently smoking 394 (24%) 353 (24%) 41 (22%) 0.643
Diabetes 508 (31%) 429 (29%) 79 (43%) ,0.0001
Death in ICD recipients 735days (median: 377 days), as the clinical trial 12-month visit window
consisted of 360+30 days and will be referred to as such throughout
this manuscript. In addition, vital status at 1 year was based on the
device tracking of the manufacturer. This was conﬁrmed when possible
(1655/1703 cases) by case report forms and/or by regular query of the
US National Death Index.
Patients of either sex who were older than 18 years of age were eli-
gible for the study if they had a signed informed consent on ﬁle at the
implanting centre prior to ICD implant and had experienced at least
one or more of the following situations: survival of at least one
episode of cardiac arrest (manifested by the loss of consciousness)
due to ventricular tachyarrhythmia, recurrent, poorly tolerated sus-
tained ventricular tachycardia (VT), prior myocardial infarction (MI),
left ventricular ejection fraction (LVEF) of  35%, and (prior to publi-
cation of MADIT-II) a documented episode of non-sustained VT, with
an inducible ventricular tachyarrhythmia.
Patients were excluded from consideration for enrolment if one or
more of the following conditions were present: a unipolar pacemaker,
ventricular tachyarrhythmias that potentially had a reversible cause,
such as digitalis intoxication, electrolyte imbalance, hypoxia, or sepsis,
or whose ventricular tachyarrhythmias had a transient cause, such as
acute MI, electrocution, or drowning, receiving ICD replacements, life
expectancy of less than 2 years due to other medical conditions, expec-
tationofa hearttransplantduring theperiod ofthe study (3–4 years),
likely to receive a mechanical tricuspid valve during the course of the
study,participationinotherclinicalinvestigations,womenwhoarepreg-
nant, and inability or refusal to complete the follow-up schedule at the
study centre in which the patient was enrolled.
Patient demographics, aetiology of ventricular function, revasculari-
zation and arrhythmia history, medications, patient determined hours
per week active, and clinical co-morbidities were assessed prior to
device implantation. Data collected at the follow-up visits included
medication changes, patient determined hours per week active, and
clinical co-morbidities.
Continuous variables were grouped into clinically meaningful
groups, and all grouped variables were summarized using frequencies
and percentages. Baseline demographics, patient history, medications,
and lab values were compared between survivors and non-survivors
using x
2 tests. Proportional hazards models were used to determine
signiﬁcant predictors of 1-year mortality. All signiﬁcant univariate pre-
dictors were included in the multivariate proportional hazards model.
One-year mortality was estimated using Kaplan–Meier methods. Ana-
lyses were performed using SAS V9.1, and P-values , 0.05 were con-
sidered signiﬁcant.
Results
Demographics
We evaluated 1703 patients (mean age: 67+12 years, 82% male,
LVEF: 32+12%) with conventional ICD indications. Patients were
followed for up to a year, and vital status was obtained for 1655
patients (97%, median follow-up: 377 days). Slightly more than
half of the population (52%) underwent ICD implant for secondary
prevention [VT/ventricular ﬁbrillation (VF)/cardiac arrest], whereas
the remainder were implanted for primary prophylaxis (largely a
MADIT-1 indication, representing 41% of the implant population).
Baseline demographics and patient history are summarized in
Table 1 for all patients where 1-year mortality status was available
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Table 2 Baseline medication/lab values of SERF study participants
Medications/lab values
Risk factor Overall (n 5 1655) Survivors (n 5 1472) Non-survivors (n 5 183) x
2
n (%) n (%) n (%) P-value
Beta-blockers 1122 (68%) 1007 (68%) 115 (63%) 0.128
Cholesterol-lowering medications 894 (54%) 815 (55%) 79 (43%) 0.002
Digitalis and derivatives 505 (31%) 428 (29%) 77 (42%) ,0.001
Anticoagulant 756 (46%) 666 (45%) 90 (49%) 0.313
Diuretic 885 (53%) 752 (51%) 133 (73%) ,0.0001
Anti-arrhythmic medications 759 (46%) 675 (46%) 84 (46%) 0.991
Hours/week physically active 0.0001
Act Hrs   5 386 (23%) 325 (22%) 61 (33%)
5 , Act Hrs   15 353 (21%) 308 (21%) 45 (25%)
15 , Act Hrs   35 359 (22%) 324 (22%) 35 (19%)
35 , Act Hrs 343 (21%) 324 (22%) 19 (10%)
Unknown 214 (13%) 191 (13%) 23 (13%)
LDL 0.740
LDL   130 673 (41%) 615 (42%) 58 (32%)
130 , LDL 115 (7%) 104 (7%) 11 (6%)
Unknown 867 (52%) 753 (51%) 114 (62%)
HDL 0.135
HDL   40 476 (29%) 427 (29%) 49 (27%)
40 , HDL 332 (20%) 308 (21%) 24 (13%)
Unknown 847 (51%) 737 (50%) 110 (60%)
K.M. Stein et al. 736(n ¼ 1655). Overall medications and lab values are summarized in
Table 2, as well as for survivors and non-survivors. Incomplete data
exist for some variables in the tables such as lipid levels.
Follow-up
A total of 183 deaths occurred within 1 year of ICD implantation,
resulting in an overall 1-year mortality rate of 16%. Among those
patients in whom the cause of death was known, 17% were
judged to have died from progressive heart failure. However, the
cause of death was known in only 67% of patients. No difference
in survival existed between primary and secondary prevention
patients (P ¼ 0.86). As shown in Table 3, a history of atrial ﬁbrilla-
tion (AF, P , 0.0001), diabetes (P ¼ 0.0001), the failure to use
cholesterol-lowering medications (P , 0.001), use of digitalis
and derivatives (P , 0.0001), use of diuretic medications
(P , 0.0001), low body mass index (BMI, P , 0.0001), increasing
age (P , 0.0001), low LVEF (P , 0.0001), low activity hours per
week (P , 0.0001), elevated resting heart rate (P ¼ 0.01), low
mean arterial pressure (MAP, P ¼ 0.007), and poor functional
status as assessed by New York Heart Association (NYHA) class
(P , 0.0001) all had a statistically signiﬁcant association with
1-year mortality in univariate analyses. Risk factors not signiﬁcantly
associated with mortality included history of syncope, MI, spon-
taneous non-sustained VT, hypertension, smoking, beta-blocker
use, anticoagulant use, anti-arrhythmic use, lipid levels, and gender.
In a multivariate model, evaluating all signiﬁcant univariate
predictors of mortality in the overall population such as AF
(P , 0.001), diabetes (P ¼ 0.004), BMI (P ¼ 0.001), low MAP
(P ¼ 0.040), and poor NYHA functional class (P ¼ 0.006) signiﬁ-
cantly predicted 1-year mortality. In the multivariate model, risk
increased with increasing symptoms of CHF (increasing NYHA
functional class). Risk was also increased for those with low or
‘normal’ BMI compared with those who were nominally ‘over-
weight’ or obese. Individuals with a BMI between 25 and 30 or
 30 had signiﬁcantly lower risks of death compared with those
with a BMI ,22. No difference in mortality existed between
those with a BMI ,22 and those with a BMI of 22–25, despite a
trend towards reduced mortality in the 22–25 BMI group. Other
subgroups in which risk was increased were patients classiﬁed as
NYHA class III compared with I, class IV compared with I, patients
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Table 3 Univariate and multivariate predictors of death in the SERF study
Risk factor Univariate model Multivariate model
Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
Atrial ﬁbrillation 2.00 1.49, 2.69 ,0.0001 1.89 1.33 ,0.001
Diabetes 1.78 1.33, 2.39 0.0001 1.68 1.18 0.004
Cholesterol-lowering medications 0.58 0.44, 0.78 ,0.001 0.74 0.52 ns
Digitalis and derivatives 1.83 1.37, 2.46 ,0.0001 1.11 0.76 ns
Diuretic 2.52 1.82, 3.49 ,0.0001 1.26 0.84 ns
BMI ,0.0001 0.001
22   BMI , 25 vs. BMI , 22 0.69 0.44, 1.07 ns 0.71 0.42 ns
25   BMI , 30 vs. BMI , 22 0.36 0.24, 0.54 0.0001 0.45 0.28 0.001
30   BMI vs. BMI , 22 0.33 0.22, 0.51 0.0001 0.40 0.24 ,0.001
Age ,0.0001 ns
65   age , 80 vs. age , 65 2.21 1.54, 3.16 ,0.0001 1.57 1.04 0.034
80   age vs. age , 65 2.39 1.46, 3.89 ,0.001 1.56 0.87 ns
LVEF ,0.0001 ns
20   LVEF , 30 vs. LVEF , 20 0.55 0.36, 0.84 0.005 0.62 0.38 ns
30   LVEF , 40 vs. LVEF , 20 0.46 0.30, 0.71 ,0.001 0.60 0.36 ns
40   LVEF vs. LVEF , 20 0.33 0.20, 0.55 ,0.0001 0.59 0.32 ns
Hours/week physically active ,0.0001 ns
5 , Act Hrs   15 vs. Act Hrs   5 0.73 0.50, 1.07 ns 0.96 0.62 ns
15 , Act Hrs   35 vs. Act Hrs   5 0.54 0.36, 0.82 0.004 0.70 0.44 ns
35 , Act Hrs vs. Act Hrs   5 0.28 0.17, 0.47 ,0.0001 0.49 0.27 0.015
Resting heart rate
Rest HR   80 vs. 80 , rest HR 0.67 0.49, 0.92 0.014 0.78 0.54, 1.13 ns
MAP
MAP   90 vs. 90 , MAP 1.52 1.12, 2.05 0.007 1.46 1.02, 2.10 0.040
NYHA ,0.0001 0.006
II vs. I 2.26 1.27, 4.01 0.006 1.50 0.79 ns
III vs. I 4.26 2.40, 7.57 ,0.0001 2.25 1.16 0.017
IV vs. I 12.00 5.64, 25.56 ,0.0001 3.94 1.61 0.003
Death in ICD recipients 737between the ages of 65–80 years compared with those ,65 years,
and patients physically active  5 h/week compared with those
physically active .35 h/week.
Discussion
Theprincipalﬁndingofthisstudyisthatinabroadpopulationunder-
going ICD implantation for routine clinical indications (VT/VF 52%,
MADIT-I 41%, MADIT-II 7%), mortality is relatively high in the
ﬁrst year after the procedure. A history of AF, diabetes mellitus,
low MAP, low BMI, and poor NYHA functional status are indepen-
dent predictors of death within a year after ICD implantation.
The observed 1-year mortality rate of 16% in the present study
is substantially higher than that observed in secondary prevention
trials (AVID: 11%,
1 CIDS: 9%,
2 and CASH: 8%
3). Similarly, mortality
was higher than observed in primary prevention trials (MADIT-II:
9%
4 and SCD-HeFT: 7%
5). Importantly, compared with these
studies, the patients in the SERF study seemed to be on average
older, on medications such as anti-arrhythmics and anticoagulant
therapy, and a larger percentage with a history of AF, VT, and/or
syncope. It is very likely that this may represent the decision in
general practice to implant ICDs in ‘sicker’ patients who would
not have been enrolled in clinical trials either due to explicit exclu-
sion criteria (e.g. exclusion of class IV patients in SCD-HeFT
5)o r
due to ‘recruitment’ bias.
6 It may also reﬂect the possibility that
participation in clinical trials may, in and of itself, lead to improved
outcomes (‘participation effect’).
7 These differences highlight the
difﬁculty in extrapolating the results of randomized clinical trials
of ICDs into general clinical practice.
These data are, however, consistent with data from a previous
retrospective study of patients undergoing ICD implantation
(mainly for a secondary prevention indication) at a single centre.
8
As in our patients, advancing age, the presence of AF, and poor
NYHA functional class were predictors of early mortality,
despite ICD implantation. Baseline renal insufﬁciency was also
shown to be a potent predictor of outcome. However, we do
not have data regarding renal function available to analyse in the
current population as the relationship between renal insufﬁciency
and mortality was not known at the time this study was designed.
The data are also consistent with those from a large registry of ICD
recipients in Ontario, Canada, in which advancing age, congestive
heart failure, and diabetes were all associated with an adverse
outcome.
9 Moreover, data from a small retrospective study of
patients undergoing implantation due to a history of VT or VF
by Schernthaner et al.
10 conﬁrm the associations between mor-
tality and low BMI, poor functional class, and AF following ICD
implant reported in our study.
The adverse prognosis associated with AF in patients with struc-
tural heart disease is well recognized.
11,12 The increased mortality
is likely multifactorial, and that increases in heart failure, stroke, and
drug toxicity may play a role.
13 Similarly, the relationship between
mortality and functional status among patients with congestive
heart failure is well recognized.
14,15 The relationship between
BMI and non-arrhythmic mortality in congestive heart failure is
less intuitive. Indeed, it seems paradoxical that overweight or
‘obese’ patients have better survival than do patients who are
‘underweight’ or normal.
16–24 This ‘obesity paradox’, also referred
to as the ‘reverse epidemiology’ of CHF, is due to the association
of increasing levels of obesity, cholesterol, and blood pressure with
better outcomes in CHF.
25 The ‘obesity paradox’ concept is clini-
cally relevant because obese patients with established CHF may be
advised not to lose weight, however the obesity itself may have
detrimental health effects.
26 Interestingly, clinical criteria com-
monly used to establish CHF have not been validated in obese indi-
viduals, in whom dyspnoea, oedema, and basilar pulmonary
crepitations may not necessarily reﬂect the presence of true
CHF,
27–29 possibly explaining the better survival in higher BMI
patients, as they may, in fact, have been healthier. However,
whether the paradox actually exists or if in fact a U-shaped HF sur-
vival curve similar to that established from the NHANES I, II, and III
data sets
30 is apparent when accounting for more severely obese
individuals is unknown. Our data in newly implanted ICD patients
indicate that the obesity paradox does exist in this patient popu-
lation and that obesity is associated with better survival.
Evidence suggests that diabetic patients derive a similar beneﬁt
from ICD therapy compared with non-diabetic patients.
31
However, diabetic patients treated conventionally (without ICDs)
tend to be much sicker and have a much higher mortality rate
than non-diabetics treated conventionally, presumably due to
more co-morbidities.
32 Thus, it is not surprising that diabetes is
associated with an increased mortality in this patient population.
The presence of low systemic arterial pressure has been shown
to be associated with a poor prognosis in patients with CHF.
33
Although low arterial pressure may limit the use of beta-blockers,
no difference in beta-blockade was evident between survivors and
non-survivors.
33 Importantly, one possible explanation for the
observation that lower BMI individuals had a poorer prognosis
than overweight or obese patients in this study may be that the
higher blood pressure in these groups allows them to better toler-
ate adequate doses of optimal pharmacological treatment.
10
It is also worth noting those variables that were not associated
with mortality. There may be a perception that the elderly and
those with the most severe left ventricular dysfunction are at par-
ticularly high risk of non-arrhythmic mortality after ICD implan-
tation. Perhaps, as a result, elderly cardiac arrest survivors are less
likely to be treated with ICD therapy than younger patients, inde-
pendent of co-morbidities.
34 In the present population, both age
and LVEF were univariate predictors of risk. However, in multi-
variatemodelling,neithervariablespredictedoutcomeindependent
of confounding factors. This supports data from clinical trials,
showing that elderly patients derive the same beneﬁt from prophy-
lacticICDimplantationasyoungerpatients.
35Likewise,therewasno
difference in outcomes according to whether the ICD was
implanted for a primary or secondary prevention indication.
Better understanding of the factors associated with mortality,
despite ICD implantation, is important in several respects. First,
by better identifying high-risk patients, physicians might be
better able to target interventions that would enhance survival.
Reduction in non-arrhythmic mortality in ICD recipients would
improve the survival advantage associated with ICD implantation
and may improve the cost-effectiveness of device therapy.
34 It is
also possible that some populations exist at such high risk of non-
arrhythmic death and that ICD implantation is futile. For example,
although prospective validation is required, the multivariate
K.M. Stein et al. 738analysis suggests that patients with the combination of poor func-
tional status, low MAP, diabetes, low BMI, and AF are at such high
risk of non-arrhythmic mortality that prophylactic ICD implan-
tation ought not to be considered. In addition, understanding
which patients are at low risk of non-arrhythmic mortality may
provide further impetus for ICD implantation in these patients
when indicated for primary prevention. Patients with only one
or two of the above risk factors still have reasonable survival,
and the mere presence of one or two of these risk factors
ought not to be considered a contraindication to device
implantation.
Our results have several important limitations. During the era in
which patients were enrolled into this study, electrophysiological
testing was routinely used for risk stratiﬁcation prior to prophylac-
tic ICD implantation. Thus, the majority of ‘primary prevention’
patients underwent implantation according to a ‘MADIT-I’ indi-
cation and not a ‘MADIT-II’ indication. Importantly, 93% of the
patients studied thus had arrhythmic histories that may indicate a
sicker population. These results therefore may not apply to
a patient population selected for ICD implantation using more
liberal criteria. Another important limitation is that QRS duration
was not collected in this study, and the QRS duration has been
shown to be predictive of VT/VF in a predominantly secondary pre-
vention trial.
36 However, QRS duration was not shown to be a pre-
dictor of mortality in patients with ICDs in a previous paper.
10
Limited data are available regarding speciﬁc causes of death in this
population as roughly one-third of the deaths were of unknown
causes. However, 17% of deaths were due to pump failure.
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